摘要
目的比较重庆市城区和偏远山区复治耐多药肺结核接受以KPO1321为主的抗痨方案疗效的差异。方法回顾性总结91例复治耐多药患者接受该方案试疗3～6月的痰菌阴转率,比较两者的差异。结果城区50例,3月痰菌阴转率为44%,6月为66%;偏远山区41例,3月痰菌阴转率为73.17%,6月为85.36%,二者比较有显著性差异。结论偏远山区复治耐多药肺结核对该方案的疗效明显优于城区。
Objective To compare the clinical efficacy between the city area and the secluded mountain area with the project of KOPTH 1321 in treating MDR-TB. Methods A total of 91 patients with MDR-TB treated for 3~6 months with the drugs. Results The sputum M. tuberculosis clearance rates were 44% in the city and 73.17% in the mountain area after 3 months (P<0.01), 66% in the city and 85.36% in the mountain area (P<0.05) after 6 months. There were singnificant differences in the two groups in the rate comparisons.Conclusion The clinical efficacy of MDR-TB in secluded mountain area is better than that in the city area.
出处
《临床肺科杂志》
2005年第4期453-454,共2页
Journal of Clinical Pulmonary Medicine
关键词
耐多药肺结核
抗痨方案
耐药率
杀菌药
multiple drug resitant pulmonary tuberculosis (MDR-TB) clinical efficacy
